Redox Modulation of Prostate Cancer

前列腺癌的氧化还原调节

基本信息

  • 批准号:
    7257520
  • 负责人:
  • 金额:
    $ 27.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-01 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The nuclear factor kappa beta (NF-kB), a redox-sensitive transcription factor, is well established as a regulator of genes coding for both proapoptosis and prosurvival proteins. It has been shown that hormone-independent prostate cancer has a high constitutive level of NF-kB and activation of NF-kB by cancer therapeutic agents can blunt the activity of these agents to cause cancer cell death. The goal of this project is to gain insight into an NF-kB mediated mechanism leading to intrinsic radiation resistance and to identify novel approaches that can be used to improve the treatment of prostate cancer. Our initial data demonstrate that androgen-independent prostate cancer has high levels of selected members of the NF-kB family and its prosurvival NF-kB target gene products including the primary antioxidant enzyme, manganese superoxide dismutase, and the antiapoptotic protein, BclXL. We also found that radiation induced activation of NF-kB in a two-wave pattern. We hypothesize that tumor cells with high levels of constitutive NF-kB will be sensitive to inhibition of the NF-kB mediated cytoprotective pathway and modulation of this pathway can improve the radiation response of aggressive prostate cancer. Parental PC-3 and its NF-kB mutant derived cell lines will be used as models for androgen-independent prostate cancer cells. Parental LNCaP and its corresponding derivatives will be used as models for androgen-dependent prostate cancer cells. Well characterized PC-3 derived as well as LNCaP derived prostate cancer cell lines will be studied in vitro and in vivo. Five-weeks-old male athymic nude mice will be used as hosts of human prostate cancer cells by orthotopic implantation in the prostate glands. Specific aim 1 is designed to identify specific members of the NF-kB family that play an important role in high intrinsic radioresistance of aggressive prostate cancer cells. Specific aim 2 is designed to test the concept that selective modulation of NF-kB or redox-based intervention can be used to enhance radiation sensitivity. Specific aim 3 is designed to validate the results from Specific aim 2 in an experimental therapeutic setting. Accomplishment of this study will enhance our understanding of the mechanisms by which members of the NF-kB family participate in cell survival. This information can serve as a rationale for the development of selective approaches that might eventually translate into significant clinical benefit.
描述(由申请人提供):核因子κ β(NF-κ B)是一种氧化还原敏感性转录因子,被公认为编码促凋亡和促存活蛋白的基因的调节因子。已经表明,非依赖性前列腺癌具有高组成性水平的NF-kB,并且癌症治疗剂对NF-kB的活化可以减弱这些药剂的活性以引起癌细胞死亡。该项目的目标是深入了解NF-kB介导的导致内在辐射抗性的机制,并确定可用于改善前列腺癌治疗的新方法。我们的初步数据表明,雄激素非依赖性前列腺癌具有高水平的选定成员的NF-κ B家族及其促生存NF-κ B靶基因产物,包括主要的抗氧化酶,锰超氧化物歧化酶,和抗凋亡蛋白,Bcl-XL。我们还发现,辐射诱导激活NF-κ B的两波模式。我们假设,具有高水平的组成性NF-κ B的肿瘤细胞将对NF-κ B介导的细胞保护途径的抑制敏感,并且该途径的调节可以改善侵袭性前列腺癌的放射反应。亲本PC-3及其NF-kB突变体衍生的细胞系将用作雄激素非依赖性前列腺癌细胞的模型。亲本LNCaP及其相应的衍生物将用作雄激素依赖性前列腺癌细胞的模型。将在体外和体内研究充分表征的PC-3衍生的以及LNCaP衍生的前列腺癌细胞系。将5周龄雄性无胸腺裸鼠用作人前列腺癌细胞的宿主,通过原位植入前列腺。具体目标1旨在鉴定在侵袭性前列腺癌细胞的高内在放射抗性中起重要作用的NF-κ B家族的特定成员。具体目标2旨在测试选择性调节NF-κ B或基于氧化还原的干预可用于增强辐射敏感性的概念。具体目标3旨在在实验治疗环境中验证具体目标2的结果。这项研究的完成将增强我们对NF-kB家族成员参与细胞存活的机制的理解。这一信息可以作为选择性方法的发展的基本原理,最终可能转化为显着的临床效益。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM H ST CLAIR其他文献

WILLIAM H ST CLAIR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM H ST CLAIR', 18)}}的其他基金

Redox Modulation of Prostate Cancer
前列腺癌的氧化还原调节
  • 批准号:
    7478583
  • 财政年份:
    2007
  • 资助金额:
    $ 27.1万
  • 项目类别:
Redox Modulation of Prostate Cancer
前列腺癌的氧化还原调节
  • 批准号:
    7843722
  • 财政年份:
    2007
  • 资助金额:
    $ 27.1万
  • 项目类别:
Redox Modulation of Prostate Cancer
前列腺癌的氧化还原调节
  • 批准号:
    8079690
  • 财政年份:
    2007
  • 资助金额:
    $ 27.1万
  • 项目类别:
Redox Modulation of Prostate Cancer
前列腺癌的氧化还原调节
  • 批准号:
    7649277
  • 财政年份:
    2007
  • 资助金额:
    $ 27.1万
  • 项目类别:
BOWMAN-BIRK PROTEASE INHIBITOR EFFECTS ON ONCOGENE EXPRESSION; COLON
BOWMAN-BIRK 蛋白酶抑制剂对癌基因表达的影响;
  • 批准号:
    3889912
  • 财政年份:
  • 资助金额:
    $ 27.1万
  • 项目类别:
INFLUENCE OF BOWMAN-BIRK PROTEINASE INHIBITOR ON ONCOGENE EXPRESSION
Bowman-BIRK 蛋白酶抑制剂对癌基因表达的影响
  • 批准号:
    3930193
  • 财政年份:
  • 资助金额:
    $ 27.1万
  • 项目类别:
CELLULAR TRANSFORMED BY TOBACCO LEAF PROTEASE INHIBIT: CHYMOTRYPSIN INHIBITOR I
烟叶蛋白酶抑制剂转化的细胞:胰凝乳蛋白酶抑制剂 I
  • 批准号:
    3868523
  • 财政年份:
  • 资助金额:
    $ 27.1万
  • 项目类别:
PROTEASE INHIBITOR ON ONCOGENE EXPRESSION, CELL PROLIFERATION & TUMORIGENESIS
癌基因表达、细胞增殖的蛋白酶抑制剂
  • 批准号:
    3909060
  • 财政年份:
  • 资助金额:
    $ 27.1万
  • 项目类别:

相似海外基金

Abnormalities in androgens and ovarian markers in reproductive-age racially and ethnically diverse women in a prospective longitudinal cohort
前瞻性纵向队列中不同种族和民族的育龄女性雄激素和卵巢标志物的异常
  • 批准号:
    10930196
  • 财政年份:
    2023
  • 资助金额:
    $ 27.1万
  • 项目类别:
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
多囊卵巢综合征中的非酒精性脂肪肝 (NAFLD):雄激素在肝损伤和 NAFLD 进展中的作用
  • 批准号:
    10735807
  • 财政年份:
    2023
  • 资助金额:
    $ 27.1万
  • 项目类别:
Sexual Differentiation of the Brain and Behaviour: Central and Peripheral Targets of Androgens
大脑和行为的性别分化:雄激素的中枢和外周目标
  • 批准号:
    RGPIN-2019-04999
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
    Discovery Grants Program - Individual
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
阐明细胞识别和响应不同水平雄激素的机制
  • 批准号:
    10418461
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
  • 批准号:
    10570208
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
  • 批准号:
    10355174
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10688086
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
Defining the impact of androgens on uterine immune cell function during endometrial tissue repair
确定子宫内膜组织修复过程中雄激素对子宫免疫细胞功能的影响
  • 批准号:
    2744296
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
    Studentship
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome
使用新型 11-含氧雄激素提高多囊卵巢综合征的诊断准确性和治疗效果
  • 批准号:
    10431620
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10525097
  • 财政年份:
    2022
  • 资助金额:
    $ 27.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了